FDA
-
-
-
-
-
-
-
FDA accepts Nuvation Bio supplemental application for IBTROZI
-
-
-
-
-
-
-
Eisai and Nuvation Bio get EU validation for lung cancer drug filing
-
-
-
-
-
-
-
Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma
-
-
-
-
-
-
-
Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology
-
-
-
-
-
-
-
Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer
-
-
-
-
-
-
-
Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
-
-
-
-
-
-
-
Nuvation Bio (NUVB) said granted FDA approval for Ibtrozi for non-small cell lung cancer
-
325,517 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

